



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 40807

Title: One more chance of fistula healing in IBD: Stem cell therapy

Reviewer’s code: 03478404

Reviewer’s country: Romania

Science editor: Jin-Lei Wang

Date sent for review: 2018-07-16

Date reviewed: 2018-07-19

Review time: 3 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input checked="" type="checkbox"/> Grade D: Fair	<input checked="" type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer’s expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input checked="" type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The invited manuscript entitled “One more chance of fistula healing in IBD: Stem cell therapy” aimed to review the published studies regarding stem cell therapies in patients with refractory fistulizing Crohn’s disease. Indeed, the studies are presented, but not really reviewed. Just some data collected from every study and inserted one above the



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

other. The review requires a paragraph to analyse, compare and interpret data (like a Discussion). Instead, after all studies being presented, the authors jumped directly to the "Conclusion". Also, there was no attention to details (examples below), there are many medical errors, something quite unusual for the number of authors. Moreover, the authors are supposed to be English native speakers. However, surprisingly, the manuscript is full of error of syntax and they should be corrected. In the actual form, the paper appears difficult to be read. Comments: 1. Title: "One more chance of fistula healing in IBD: Stem cell therapy" and Short title: "Stem cell therapy for fistula in Crohn's disease"; but fistula appears only in Crohn's disease, there is nothing in UC or IBD-U 2. Abstract: "Patients with fistulizing inflammatory bowel disease"; same comment 3. Same for the CORE TIP: "stem cell therapy to treat fistulizing inflammatory bowel disease" 4. INTRODUCTION: 4.1. The authors wrote "indeterminate colitis", but the actual term is IBD-U (unclassified). "Indeterminate colitis" is the old term. 4.2. The authors wrote: "Inflammatory bowel disease (IBD), including Crohn's disease (CD), ulcerative colitis, and indeterminate colitis, is a very complicated unique spectrum of disease processes, ranging from relatively asymptomatic to daily complications of significant pain and fistulizing disease" This is totally wrong. Fistulas do not develop in UC or IBD-U. How would the authors provide the best available scientific evidence if they do not know aspects that students are supposed to know? 4.3. "Some patients will do well and achieve complete remission with newer biological agents". This is not correct. What "NEWER" biological agents? Remission could be achieved in some patients with the first biologic agent ever described and used, which is Infliximab. 4.4. "Here is where the use of stem cell therapy for fistulizing CD has been introduced." Please rephrase, this is not spoken language. 4.5. The authors wrote "The outcomes of safety and efficacy using this innovative treatment are presented throughout and are summarized in Table 1". But, Table 1 does not summarize it at all, it contains too many



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

data, it has to be totally re-written. Safety is not mentioned separately in Table 1. Type of study should be included. Same data is written in the text and in Table 1. Data should not be redundant. A short legend should be inserted under Table 1, for abbreviations. 5. Autologous Adipose Tissue Derived Stem Cell Therapy Trials 5.1. The authors wrote “In 2003, one of the first case reports for fistulizing CD using ASC for CD-related rectovaginal fistulas (CRRVF) was reported. This utilized ASC for a patient with refractory disease to infliximab and placement of setons, with resultant resolution of symptoms in one week after local injection with no reoccurrence after three months [5].” However, reference [5] is from 2016. In fact, reference [5] should be Garcia-Olmo, which appears in the References as nr. 17. Given the number of authors of this review, this mistake is quite surprising. 5.2 The authors wrote “Next, Cho et al. studied autologous ASC in a phase 1 non-randomized, open-label dose escalation trial with 10 patients enrolled [6]. But, reference [6] is Lee and Cho 2013 is not mentioned AT ALL. Also, wrong reference is mentioned in Table 1. Again, someone may wonder if the authors read their manuscript. There is only reference to Cho 2015. 6. Autologous Bone Marrow Derived Stem Cell Therapy Trials: The authors wrote “In 2007-2014”; probably they wanted to write “Between” 7. Allogenic Adipose Tissue Derived Stem Cell Therapy Trials 7.1. It is enough to write “De la Portilla”, not necessary to write the second author. Also in Table 1. 7.2. The authors wrote “Published this year, Panes et al.”; however, this is not reflected in the reference of the manuscript, which mentions only 2017, as in Table 1. Correct reference is “Gastroenterology. 2018 Apr;154(5):1334-1342.e4” Epub was in 2017. But then this is not “this year” 7.3. The authors wrote “Wainstein et al. also published a single center prospective observational pilot study conducted by 2013-2016”; please replace “by” 8. Conclusion 8.1. Should start with “In this review”... 8.2. The authors wrote “In this review, we highlight the progression of utilization of stem cell therapy in fistulizing IBD”. Again, fistula is considered in all IBD cases, not only CD.



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

8.3. Their first sentence could be used for “Future perspectives”, which are totally missing (“Currently on the horizon, there...”) 9. I am not sure where this paper is supposed to be published. It was mentioned “World Journal of Clinical Cases”. However, the authors wrote “Name of Journal: World Journal of Case Reports” 10. Text and references are not written according to the Format requirements. Attention to details is of paramount importance. Rules should be the same for all authors.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No

Re-review:

After carefully reviewing it, I can say I am very pleased to see that my comments/suggestions contributed to a much better version of the paper. The manuscript has been really improved.

The only minor comment is that usually “Future perspectives” are inserted at the end of any manuscript, after Conclusion. Authors wrote them in the “Discussion” paragraph.



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

However, I think being original is sometimes not so bad.

I recommend this paper to be published.



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 40807

Title: One more chance of fistula healing in IBD: Stem cell therapy

Reviewer's code: 02941507

Reviewer's country: Greece

Science editor: Jin-Lei Wang

Date sent for review: 2018-07-16

Date reviewed: 2018-07-21

Review time: 5 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input checked="" type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This is a well-written review concerning the role of stem cell treatment of patients with refractory fistulizing Crohn's disease. The authors reviewed the available data in a systemic way describing the key results of the available clinical studies. The paper should be published however after some modifications. The conclusion part should be



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

extended including the suggestion(s) and practical guidance(s) of the authors to the reader. Certainly everyone dealing with the care of patients with fistulizing Crohn's disease knows the significance of the application of stem-cell therapy in these patients. Nevertheless the important part of this knowledge is the way and the possibility of applying this kind of treatment in the every day's clinical setting.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No